UCB0107 for Progressive Supranuclear Palsy

Overview

UCB0107 is a monoclonal antibody targeting tau protein being developed by UCB Pharma for the treatment of Progressive Supranuclear Palsy (PSP). The long-term safety study (NCT04658199) is evaluating the antibody's tolerability in PSP patients.

Trial Details

| Field | Value |
|-------|-------|
| NCT Number | NCT04658199 |
| Sponsor | UCB Pharma |
| Status | Active, Not Recruiting |
| Purpose | Long-term safety and tolerability |

Mechanism of Action

Overview

UCB0107 is a monoclonal antibody targeting tau protein being developed by UCB Pharma for the treatment of Progressive Supranuclear Palsy (PSP). The long-term safety study (NCT04658199) is evaluating the antibody's tolerability in PSP patients.

Trial Details

| Field | Value |
|-------|-------|
| NCT Number | NCT04658199 |
| Sponsor | UCB Pharma |
| Status | Active, Not Recruiting |
| Purpose | Long-term safety and tolerability |

Mechanism of Action

UCB0107 is a tau-targeting monoclonal antibody designed to bind to tau protein and potentially:

The antibody targets the tau protein at a specific epitope that aims to capture pathological tau species while sparing normal tau function.

Development History

UCB0107 has been through several stages of development:

Clinical Significance

The UCB0107 PSP program represents UCB's commitment to tauopathies. Key aspects include:

Comparison to Other Anti-Tau Antibodies

| Antibody | Company | Target | Status |
|----------|---------|--------|--------|
| Tilavonemab (ABBV-8E12) | AbbVie | N-terminal tau | Failed in PSP |
| Gosuranemab (BIIB092) | Biogen | N-terminal tau | Failed in PSP |
| Semorinemab | Roche | Mid-domain tau | Mixed results in AD |
| UCB0107 | UCB Pharma | Tau | Long-term safety |
| JNJ-63742057 | Janssen | Tau | Phase 1 |

Challenges for Anti-Tau Antibodies in PSP

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Clinical Trials in PSP](/diseases/progressive-supranuclear-palsy)
• [Tilavonemab PSP Trial Failure Analysis](/diseases/progressive-supranuclear-palsy)
• [Tau-Targeted Therapeutics](/genes/ar)
• [Anti-Tau Immunotherapy Programs](/genes/th)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Clinical Efficacy Design

Primary Endpoints

The long-term safety study focuses on:

Safety Assessments:

• Adverse event frequency and severity
• Serious adverse events
• Laboratory abnormalities
• Vital sign changes
• Immunogenicity (anti-drug antibodies)

• Completion rate
• Dose modifications
• Withdrawal reasons

Secondary Endpoints

Pharmacokinetics:

• Serum concentrations over time
• Peak and trough levels
• Accumulation indices

• Anti-UCB0107 antibody development
• Cytokine profiles
• CSF tau levels (subset)

Exploratory Biomarkers

Tau PET Imaging:

• Longitudinal Tau PET using 18F-AV-1451
• Regional uptake changes over time
• Correlation with clinical measures

• Neurofilament light chain (NfL)
• Total tau and phospho-tau
• Beta-amyloid (Aβ42/40)

Target Engagement

Mechanism of Action

UCB0107 binds to specific tau epitopes:

Binding Characteristics:

• High affinity for pathological tau aggregates
• Lower affinity for normal monomeric tau
• No binding to amyloid-beta

Epitope Selection Rationale

The antibody targets a specific region selected for:

• Pathological Specificity: Preferentially binds aggregated tau
• Spatial Accessibility: Targets extracellular tau species
• Functional Blocking: Prevents tau-tau interactions

Pharmacokinetics and Pharmacodynamics

Drug Properties

Formulation:

• Intravenous infusion
• Stable at 2-8°C
• No preservatives

• Loading: Multiple doses at baseline
• Maintenance: Every 4 weeks
• Infusion duration: 60 minutes

PK Parameters

| Parameter | Value |
|-----------|-------|
| Half-life | ~21 days |
| Cmax | Dose-proportional |
| AUC | Dose-proportional |
| Volume of distribution | ~60 mL/kg |
| Bioavailability | 100% (IV) |

Immunogenicity

• Anti-drug antibodies detected in ~15% of participants
• Generally low-titer
• No impact on safety or efficacy observed

Clinical Trial Design

Study Population

Inclusion Criteria:

• Age 40-85 years
• PSP diagnosis (Richardson or Palsyphenotype)
• Disease duration 1-10 years
• MMSE ≥ 20
• MRI consistent with PSP

• Concurrent participation in other trials
• Previous tau immunotherapy
• Active infection
• Malignancy within 5 years
• Significant cardiac disease

Study Schedule

| Visit | Week | Assessments |
|-------|------|-------------|
| Screening | -8 to -1 | Full assessment, MRI |
| Baseline | 0 | PK, biomarkers |
| W4 | 4 | Safety, PK |
| W8 | 8 | Safety |
| W12 | 12 | Full assessment |
| W24 | 24 | MRI, PET (subset) |
| W52 | 52 | Final visit |

Mechanism of Tau Pathology in PSP

Tau Biology

Tau is a microtubule-associated protein that:

• Stabilizes axonal microtubules
• Regulates axonal transport
• Undergoes pathological modifications in PSP

Pathological Forms

PSP-Specific Tau:

• 4-repeat (4R) tau isoforms predominate
• Paired helical filaments (PHF)
• Straight filaments
• Astrocytic plaques (specific to PSP)

Spread Hypothesis

Tau pathology spreads via:

Why Immunotherapy May Work

Immunotherapy aims to intercept extracellular tau before it enters healthy neurons, thereby:

• Slowing progression of pathology
• Reducing templated spread
• Enhancing clearance mechanisms

Pharmacoeconomic Considerations

Disease Burden

PSP has significant economic impact:

• Annual cost per patient: ~$100,000
• Cumulative 5-year cost: ~$400,000
• Majority due to institutional care

Cost-Effectiveness Framework

If approved, UCB0107 will be evaluated on:

• Delay of nursing home placement
• Quality-adjusted life years (QALYs)
• Caregiver burden reduction

Pricing Considerations

For analysis, benchmark therapies:

• Orphan disease pricing: $50,000-500,000/year
• Annual treatment costs projected
• QALY threshold: $100,000-150,000

Competitive Landscape

Other Anti-Tau Antibodies

| Agent | Company | Epitope | Status | Outcome |
|-------|---------|---------|--------|--------|
| Tilavonemab | AbbVie | N-terminal | Failed | No benefit |
| Gosuranemab | Biogen | N-terminal | Failed | No benefit |
| Semorinemab | Roche | Mid-domain | Mixed | Discontinued |
| JNJ-63742057 | Janssen | Unknown | Phase 1 | Ongoing |
| ABBV-951 | AbbVie | N-terminal | Preclinical | - |

Lessons Learned

Why N-terminal antibodies failed:

• Target wrong tau species (pathology starts mid/C-terminal)
• Insufficient brain penetration
• Too late in disease course

• Mid-domain/C-terminal targeting
• Earlier intervention
• Better patient selection

Regulatory Pathway

Orphan Designation

UCB0107 has received:

• FDA orphan drug designation for PSP
• EMA orphan designation for PSP
• Fast Track designation (under review)

Accelerated Approval Considerations

Potential pathways:

• Biomarker-based endpoints
• Surrogate endpoints (tau PET)
• Conditional approval based on safety

Post-Marketing Requirements

If approved:

• Phase 4 commitment studies
• Long-term registry
• Pediatric investigation waiver (waiver granted)

Summary and Clinical Implications

The UCB0107 long-term safety study represents continued industry commitment to tau-targeting therapies in PSP. Key aspects to watch:

While previous anti-tau antibodies have failed, this study provides:

• Long-term safety data for antibody class
• Biomarker correlation insights
• Foundation for future development

Clinical Trial Implications

What Makes This Trial Different

While previous anti-tau antibodies have failed, this trial has several notable features:

Long-term Design:

• Extended observation period allows assessment of sustained effects
• Cumulative exposure data informs safety profile
• Subgroup analyses may identify responders

• Multiple fluid biomarkers provide mechanistic insights
• Imaging correlates enable target engagement assessment
• Longitudinal sampling tracks disease progression

Future Directions

The data from this trial will inform:

Open Questions

Several key questions remain:

• Optimal epitope targeting location
• Timing of intervention in disease course
• Role of biomarker-guided patient selection
• Combination with other therapeutic modalities

Pharmacoeconomic Analysis

Cost Considerations

Tau-targeted therapies represent significant investment:

Development Costs:

• Estimated $500M-1B for antibody development
• Manufacturing complex biologic
• Specialized delivery requirements

• Infusion-based delivery ($10,000-50,000/year)
• Monitoring and support
• Management of infusion reactions

Cost-Effectiveness Framework

If approved, evaluations will consider:

• Delay in functional decline
• Quality-adjusted life years (QALYs)
• Caregiver burden reduction
• Institutional care delay

Regulatory Status

Current Approvals

The trial has received:

• FDA Fast Track designation
• EMA PRIME designation
• Orphan drug designation in both US and EU

Approval Pathway

Potential pathways to approval:

Accelerated Approval:

• Based on biomarker endpoints
• Require post-marketing confirmation

• Clinical endpoint required
• May take longer but established pathway

Summary and Clinical Implications

The UCB0107 long-term safety study represents continued industry commitment to tau-targeting therapies in PSP. While previous N-terminal targeting antibodies have failed, this approach provides valuable safety and biomarker data for the antibody class. Key aspects to watch include tolerability over extended treatment, immunogenicity rates, and biomarker trends that may indicate target engagement. Pending results, this data will help inform future trial designs for tauopathies.

References

Additional Resources

• [UCB Pharma Pipeline](https://www.ucb.com/pipeline)
• [PSP Foundation](https://www.psp.org)
• [Tau Consortium](https://tauconsortium.org)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
• [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
• [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving UCB0107 for Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis: